Posted by Michael Wonder on 21 Mar 2024
AstraZeneca caps patient out of pocket costs at $35 per month for its US inhaled respiratory portfolio
18 March 2024 - Expanded savings programs build on company’s longstanding commitment to addressing barriers to access and affordability for patients
AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.
